We are live on ! Find out more
BNGO icon

Bionano Genomics

50 hedge funds and large institutions have $1.75M invested in Bionano Genomics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

460% more call options, than puts

Call options by funds: $56K | Put options by funds: $10K

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

6% more funds holding

Funds holding: 4750 (+3)

0.01% less ownership

Funds ownership: 0.11%0.1% (-0.01%)

29% less capital invested

Capital invested by funds: $2.47M → $1.75M (-$720K)

Holders
50
Holders Change
+3
Holders Change %
+6.38%
% of All Funds
0.66%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
11
Reduced
9
Closed
7
Calls
$56K
Puts
$10K
Net Calls
+$46K
Net Calls Change
-$36K

BNGO Hedge Fund Activity: Q4 2024 in Review

50 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q4 2024, worth a combined $1.75M — down 29% from $2.47M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new BNGO positions and 7 closed out — a net gain of 5 holders — while 11 added to existing stakes and 9 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $145K. The largest seller was GMT Capital, exiting entirely with an estimated $241K sold.

  • 50 institutional investors held Bionano Genomics (BNGO) as of Q4 2024, up from 47 in Q3 2024.
  • Funds reported $1.75M of Bionano Genomics stock for Q4 2024, down 29% quarter-over-quarter.
  • 12 funds opened new Bionano Genomics positions in Q4 2024 and 7 closed out, a net change of +5 holders.
  • The largest Bionano Genomics buyer in Q4 2024 was Morgan Stanley, an estimated $145K added.
  • The largest Bionano Genomics seller in Q4 2024 was GMT Capital, an estimated $241K sold.

Based on aggregated 13F filings for Q4 2024.